《大行報告》匯豐研究首予思摩爾(06969.HK)「買入」評級 目標價65元
匯豐環球研究發表報告指,思摩爾(06969.HK)為全球最大電子煙霧化芯片供應商,市佔率達19%,該行相信電子煙銷售於2021年至2024年期間將會高速增長,年複合增長率達31%,思摩爾亦勢將受惠。中國政府早前公布對電子煙規管,思摩爾股價累跌27%,惟該行指由於思摩爾大部份業務來自海外,相信相關政策對思摩爾影響有限。
該行料思摩爾2020年至2023年收入複合增長率可達36%,期間盈利複合增長率同樣為36%,毛利率亦將自53%提升至55%。首予思摩爾「買入」評級,目標價65元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.